Shareholders Corner
Filings with the exchange
- Update on Acquisition – ABCD Technologies
- Disclosure of Related Party Transaction for the half year ended 31st March 2023
- Exchange Notification: Glenmark divests its Tail Brands in the dermatology segment for India and Nepal to ERIS
- Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
- Glenmark Pharmaceuticals Ltd. to divest its Cardiac brand, Razel®, in India and Nepal to J.B. Chemicals & Pharmaceuticals Limited
- Investors Presentation - Glenmark Pharmaceuticals Limited Investor Day 2022
- Glenmark Pharmaceuticals Limited ‐ Investor Day 2022
- Disclosure of Related Party Transactions for the half year ended 31st March, 2022
- Notice of Early Redemption by Glenmark Pharmaceuticals Limited to the holders of its U.S.$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities Due 2022 ("Bonds").
- Outcome Of The Board Meeting Held On 7th April, 2022
- Intimation of buyback by Glenmark Pharmaceuticals Limited in respect of the US$ 200,000,000 2.00% Resettable Onward Starting Equity-Linked Securities due 2022 (the "FCC Bonds")
- Operations Committee Meeting to authorize the repurchase of outstanding U.S.$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities Due 2022 ("Bonds") by Glenmark Pharmaceuticals Limited and issuance of the Notice of Early Redemption by the Company to the holders of the Bonds
- Intimation of change in name of the Company's Registrar and Share Transfer Agent
- Disclosure of Related Party Transactions for the half year ended 30th September, 2021
- Update on listing of equity shares of Glenmark Life Sciences Limited
- Initial public offering ("Offer'') of equity shares of our wholly owned subsidiary "Glenmark Life Sciences Limited"
- Filing and approval of the Red Herring Prospectus ("RHP") dated July 19, 2021 of our wholly owned subsidiary "Glenmark Life Sciences Limited" in connection with its proposed initial public offering of equity shares ("Offer" or "IPO")
- Annual Disclosure to be made by an entity identified as a Large Corporate
- Announcement by Glenmark Pharmaceuticals Limited (the “Company”) of the results of the Proposal in respect of its U.S.$200,000,000 2.00 per cent. Resettable Onward Starting Equity‐linked Securities Due 2022 (“Bonds”)
- Announcement of the Results of the Offer in respect of U.S.$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities Due 2022
- Operation Committee Approval for Tender Offer and Consent Solicitation - 2.00 per cent. Resettable Onward Starting Equity-linked Securities due 2022 (ISIN: XS1426780125)
- Tender Offer and Consent Solicitation - 2.00 per cent. Resettable Onward Starting Equity-linked Securities due 2022 (ISIN: XS1426780125)
- Outcome of the Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt
- Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt
- Intimation under the SEBI (LODR) Regulations, 2015 dated January 15, 2021
- Intimation under SEBI (LODR) Regulations, 2015 dated December 9, 2020
- Intimation under SEBI (LODR) Regulations, 2015 dated December 1, 2020
- Intimation under SEBI (LODR) Regulations, 2015 dated November 20, 2020
- Cessation of Directorship – Mr. Milind Sarwate
- Outcome of Board meeting for appointment of Independent Director and Statutory Auditor – 14th Aug, 2020
- Disclosure of Related Party Transactions under Regulation 23(9) of the SEBI (LODR) Regulations, 2015 – 31st March, 2020
- Glenmark's response to DCGI letter seeking clarification on FabiFlu®
- Annual Secretarial Compliance Report FY 2019-20
- Glenmark introduces Favipiravir (FabiFlu®) for the treatment of mild to moderate COVID-19 in India
- Indian regulator approves Favipiravir for the treatment of mild to moderate COVID-19 in India
- Board Meeting Intimation – 26th June, 2020
- Board Meeting related Intimation
- Disclosure under Regulation 30 of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015
- Disclosure of Related Party Transactions under Regulation 23(9) of the SEBI (LODR) Regulations, 2015 – 30th September, 2019
- Change of name of Registrar and Share Transfer Agent from “Karvy Fintech Private Limited” to “KFin Technologies Private Limited”
